|
rs1057519975
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A mutation does not necessarily alter the protein function and since not all altered tumor protein p53 (TP53) conformations lead to the same biological properties, we studied Cys135Arg TP53 gene mutation in squamous cell type of non-small cell lung cancers (NSCLCs), by polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) and direct sequencing.
|
17914575 |
2007 |
|
rs1800372
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition, we detected the rare R213R (rs1800372, minor allele frequency: 0.0054) polymorphism in 7.2% of the patients and are the first to show the significant association with TP53 mutations in non-small cell lung cancer adenocarcinoma patients (p = 0.003).
|
28240049 |
2017 |
|
rs1042522
|
|
|
0.070 |
GeneticVariation |
BEFREE |
In summary, we found that the p53 p. Pro72Arg, MDM2 c.14 + 309T > G and MDM2 c.-461C > G polymorphisms are associated with toxicity risks following platinum-based chemotherapy treatment in advanced NSCLC patients.
|
25482940 |
2014 |
|
rs1131691014
|
|
|
0.070 |
GeneticVariation |
BEFREE |
In summary, we found that the p53 p. Pro72Arg, MDM2 c.14 + 309T > G and MDM2 c.-461C > G polymorphisms are associated with toxicity risks following platinum-based chemotherapy treatment in advanced NSCLC patients.
|
25482940 |
2014 |
|
rs878854066
|
|
|
0.070 |
GeneticVariation |
BEFREE |
In summary, we found that the p53 p. Pro72Arg, MDM2 c.14 + 309T > G and MDM2 c.-461C > G polymorphisms are associated with toxicity risks following platinum-based chemotherapy treatment in advanced NSCLC patients.
|
25482940 |
2014 |
|
rs1042522
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
|
16499995 |
2006 |
|
rs1131691014
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
|
16499995 |
2006 |
|
rs878854066
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
|
16499995 |
2006 |
|
rs12947788
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Interestingly, TP53 polymorphisms in intron 7 (rs12947788 and rs12951053) were more frequently identified in asbestos-exposed NSCLC (P = 0.046) and MPM patients than in unexposed patients (P < 0.001 and P = 0.012, respectively).
|
23435014 |
2013 |
|
rs12951053
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Interestingly, TP53 polymorphisms in intron 7 (rs12947788 and rs12951053) were more frequently identified in asbestos-exposed NSCLC (P = 0.046) and MPM patients than in unexposed patients (P < 0.001 and P = 0.012, respectively).
|
23435014 |
2013 |
|
rs762846821
|
|
|
0.020 |
GeneticVariation |
BEFREE |
KRAS G12D and STK11 mutations confer poor prognoses for patients with KRAS-mutant NSCLC.
|
31200821 |
2019 |
|
rs1042522
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Our results suggest that the genotype of the Arg72Pro polymorphism may modulate the frequency of TP53 mutations in non-small-cell lung cancer.
|
17932356 |
2007 |
|
rs1131691014
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Our results suggest that the genotype of the Arg72Pro polymorphism may modulate the frequency of TP53 mutations in non-small-cell lung cancer.
|
17932356 |
2007 |
|
rs878854066
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Our results suggest that the genotype of the Arg72Pro polymorphism may modulate the frequency of TP53 mutations in non-small-cell lung cancer.
|
17932356 |
2007 |
|
rs1042522
|
|
|
0.070 |
GeneticVariation |
BEFREE |
The purpose of the study was to investigate whether polymorphisms of p53 codon 72 (Arg72Pro) and MDM2 SNP309 (309T>G) affect p53 expression and the clinical outcome of patients with advanced nonsmall cell lung cancer (NSCLC).
|
18618574 |
2008 |
|
rs1131691014
|
|
|
0.070 |
GeneticVariation |
BEFREE |
The purpose of the study was to investigate whether polymorphisms of p53 codon 72 (Arg72Pro) and MDM2 SNP309 (309T>G) affect p53 expression and the clinical outcome of patients with advanced nonsmall cell lung cancer (NSCLC).
|
18618574 |
2008 |
|
rs878854066
|
|
|
0.070 |
GeneticVariation |
BEFREE |
The purpose of the study was to investigate whether polymorphisms of p53 codon 72 (Arg72Pro) and MDM2 SNP309 (309T>G) affect p53 expression and the clinical outcome of patients with advanced nonsmall cell lung cancer (NSCLC).
|
18618574 |
2008 |
|
rs1042522
|
|
|
0.070 |
GeneticVariation |
BEFREE |
This study aims to determine the value of codon 72 missense polymorphic variant genotyping, TP53 R72P, as a prognostic factor in NSCLC patients.
|
29286914 |
2018 |
|
rs1131691014
|
|
|
0.070 |
GeneticVariation |
BEFREE |
This study aims to determine the value of codon 72 missense polymorphic variant genotyping, TP53 R72P, as a prognostic factor in NSCLC patients.
|
29286914 |
2018 |
|
rs878854066
|
|
|
0.070 |
GeneticVariation |
BEFREE |
This study aims to determine the value of codon 72 missense polymorphic variant genotyping, TP53 R72P, as a prognostic factor in NSCLC patients.
|
29286914 |
2018 |
|
rs1042522
|
|
|
0.070 |
GeneticVariation |
BEFREE |
This study investigated whether the functional polymorphisms in P53 pathway genes, P53 Arg72Pro (rs1042522), P73 G4C14-to-A4T14 (rs2273953 and rs1801173), and MDM2 T309G (rs2279744), alone or in combination, affect survival in advanced non-small cell lung cancer (NSCLC) patients.
|
21841506 |
2011 |
|
rs1131691014
|
|
|
0.070 |
GeneticVariation |
BEFREE |
This study investigated whether the functional polymorphisms in P53 pathway genes, P53 Arg72Pro (rs1042522), P73 G4C14-to-A4T14 (rs2273953 and rs1801173), and MDM2 T309G (rs2279744), alone or in combination, affect survival in advanced non-small cell lung cancer (NSCLC) patients.
|
21841506 |
2011 |
|
rs878854066
|
|
|
0.070 |
GeneticVariation |
BEFREE |
This study investigated whether the functional polymorphisms in P53 pathway genes, P53 Arg72Pro (rs1042522), P73 G4C14-to-A4T14 (rs2273953 and rs1801173), and MDM2 T309G (rs2279744), alone or in combination, affect survival in advanced non-small cell lung cancer (NSCLC) patients.
|
21841506 |
2011 |
|
rs762846821
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Using genetically engineered mouse models (GEMMs) for human non-small-cell lung cancer (NSCLC), we found that deletion of the essential autophagy gene, Atg7, in KRAS(G12D)-driven NSCLC inhibits tumor growth and converts adenomas and adenocarcinomas to benign oncocytomas characterized by the accumulation of respiration-defective mitochondria.
|
23959381 |
2013 |
|
rs587782289
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Using select c-CBL somatic mutations such as S80N/H94Y, Q249E and W802* (obtained from Caucasian, Taiwanese and African-American samples, respectively) transfected in NSCLC cell lines, there was increased cell viability and cell motility.
|
20126411 |
2010 |